We have the pleasure to announce the availability of the above-mentioned study, which takes a global look at the immunoglobulin market and looks to its prospects for growth in the future. Because immunoglobulin (IG) is the dominant revenue-generating therapeutic protein from plasma fractionation, its future growth rate profoundly impacts the entire industry on a number of levels, including plasma requirements forecasting, plasma collection capacity planning, manufacturing infrastructure planning, projection of per-liter plasma valuation, and revenue and profit forecasting.  For these and other reasons, projection of the likely future demand for IG is of critical importance.

This new report takes a deep look at current IG usage levels around the globe, and details how IG is used by medical specialty and key indications across all five geographic regions (North America, South America, Asia/Pacific, Europe, and the Middle East/Africa).  MRB’s forecast model analyzes both key drivers of IG growth and risks to future growth, taking into account how the interaction of plasma supply and IG demand can be expected to influence price patterns globally over the next 7 years. This report identifies IG usage in over 80 countries in 2019 and 2020, including breakdowns of IVIG and SCIG market shares by geographic region.  For 2021 through 2027, the report forecasts country-level IG product sales in units, and regional sales in both U.S. dollars and average manufacturer-level price per gram.  Also detailed for each region are key growth drivers and expected growth rates by region over the forecast period. The COVID19 pandemic’s effect plasma collections and consequently the supply of IG is heavily discussed as it significantly effects the next few years of sales around the world.

Compared with a few years ago, there is increasing realization that new competition to IG usage in several autoimmune conditions including Myasthenia Gravis, ITP and CIDP is fast approaching. Of important concern among plasma fractionation companies, is the effect that new therapies will have on IG demand in these conditions.

 

TABLE OF CONTENTS

Page

EXECUTIVE SUMMARY                                                                                       5
1. INTRODUCTION                                                                                              15

2. FORECAST ASSUMPTIONS                                                                           18

3. IMMUNOGLOBULIN USAGE & FORECAST IN NORTH AMERICA              24
2020 IG Usage in North America 24
Current IG Usage by Indication in the United States 25
Neurological IG Usage in the United States 26
Primary & Secondary Immunodeficiency IG Usage in the United States 27
Canada Current IG Usage by Indication 32
Forecast to 2027 in North America 37
Growth Drivers of IG Usage over Forecast Period 40

4. IMMUNOGLOBULIN USAGE & FORECAST IN EUROPE                             47
2020 IG Usage in Europe 47
United Kingdom Current IG Usage by Indication 48
France Current IG Usage by Indication 54
Belgium Current IG Usage by Indication 59
Neurological Immunoglobulin Usage in Europe 65
Primary Immunodeficiency and Immunoglobulin Usage in Europe 66
Secondary Immunodeficiency and Immunoglobulin Usage in Europe 71
Forecast to 2027 in Europe 71
Growth Drivers of IG Usage over the Forecast Period 81

5. IMMUNOGLOBULIN USAGE & FORECAST IN ASIA & PACIFIC                 87
2020 IG Usage in Asia Pacific 87
Australia Current IG Usage by Indication 89
Chinese IG Usage by Indication 94
Primary & Secondary Immunodeficiency and Immunoglobulin Usage in Asia Pacific 98
Neurological and Other Immunoglobulin Usage in Asia Pacific 99
Forecast to 2027 in Asia Pacific 100
Growth Drivers of IG Usage over Forecast Period 107

6. IMMUNOGLOBULIN USAGE & FORECAST IN THE MIDDLE EAST & AFRICA 112
2020 IG Usage in Middle East & Africa 112
Primary Immunodeficiency and Immunoglobulin Usage in Africa 114
Other Immunoglobulin Usage in Latin America 119
Forecast to 2027 in Middle East & Africa 120
Growth Drivers of IG Usage over Forecast Period 129

7. IMMUNOGLOBULIN USAGE & FORECAST IN LATIN AMERICA            134
2020 IG Usage in Latin America 134
Primary & Secondary Immunodeficiency and IG Usage in Latin America 135
Neurological Immunoglobulin Usage in Latin America 141
Forecast to 2027 in Latin America 143
Growth Drivers of IG Usage over Forecast Period 152

8. FORECAST OF THE WORLDWIDE IMMUNOGLOBULIN DEMAND      157
2020 Global IG Usage 157
Global IG Forecast from 2020 to 2027 163
Growth by Year 163
Average Annual Growth from 2020-2027 165
IG Growth Expectations by Specialties/Diseases 167